Michelle Gilson
Stock Analyst at Morgan Stanley
(1.18)
# 2,826
Out of 4,667 analysts
30
Total ratings
31.82%
Success rate
-4.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Equal-Weight | $12 → $15 | $6.95 | +115.83% | 3 | Jun 6, 2024 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $55.92 | -46.35% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $4.86 | +249.79% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $122.64 | +59.82% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $18.26 | +146.44% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $11.27 | +574.36% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $63.45 | +43.42% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jun 6, 2024
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $6.95
Upside: +115.83%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $55.92
Upside: -46.35%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $4.86
Upside: +249.79%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $122.64
Upside: +59.82%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $18.26
Upside: +146.44%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $11.27
Upside: +574.36%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $63.45
Upside: +43.42%